By Combat Research
What Is KPV?
KPV is a tripeptide fragment derived from alpha-Melanocyte Stimulating Hormone (α-MSH), specifically from its C-terminal region. It has gained interest in biomedical research for its:
- Anti-inflammatory activity
- Barrier-protective effects (gut, skin, epithelial)
- Potential antimicrobial properties
Sequence: Lysine–Proline–Valine (Lys-Pro-Val)
KPV is non-hormonal and lacks the melanotropic (pigment-affecting) effects of full-length α-MSH, making it a selective anti-inflammatory research tool.
🔬 Mechanism of Action
KPV exerts its effects primarily by interfering with inflammatory signaling cascades, most notably:
- Inhibition of NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells)
- Reduction in pro-inflammatory cytokines such as TNF-α, IL-6, IL-1β
- Stabilization of epithelial tight junction proteins
Research Mechanism Highlights:
| Pathway | Effect |
|---|---|
| NF-κB | Downregulation, leading to suppression of inflammation |
| TNF-α / IL-6 | Decreased production in epithelial and immune cells |
| Melanocortin 1 Receptor (MC1R) | Partial interaction; modulates without full receptor activation |
| Reactive Oxygen Species (ROS) | Indirect antioxidant effect by reducing cytokine-induced stress |
📚 Preclinical Research Applications
KPV is studied across a variety of inflammation-driven and epithelial-barrier disorders:
| Research Area | Model Example |
|---|---|
| IBD / Colitis | DSS-induced colitis in mice |
| Atopic Dermatitis / Psoriasis | Topical inflammation in skin models |
| Wound Healing | Epithelial barrier repair assays |
| Sepsis / Gut Barrier Dysfunction | LPS-induced gut leak models |
| Intestinal permeability | Tight junction studies in Caco-2 cells |
📊 Preclinical Dosing Overview (Animal and In Vitro Studies)
While KPV is not FDA-approved and not for human use, here are reported research doses in published literature.
| Model | Route | Dose | Frequency | Notes |
|---|---|---|---|---|
| DSS-induced colitis (mice) | IP or enema | 1–5 mg/kg | Daily | Reduced colon inflammation and weight loss |
| Skin inflammation (mouse) | Topical | 100–500 µg/cm² | 1–2x daily | Reduced swelling and cytokines |
| Cell cultures | Media supplement | 10–100 µM | — | Dose-dependent suppression of TNF-α response |
⚠️ These are not guidelines for human use — only for laboratory planning within animal or in vitro systems.
🧪 Handling, Storage, and Stability
To preserve activity and reproducibility:
| Factor | Recommendation |
|---|---|
| Lyophilized Storage | −20°C in a desiccated, light-protected environment |
| Reconstituted Storage | 4°C for short-term (3–7 days); aliquot and freeze at −20°C for longer |
| Solvent | Sterile water or phosphate-buffered saline (PBS) |
| Stability | Stable at room temp for brief periods but sensitive to repeated freeze-thaw cycles |
✅ Summary of Key Research Attributes
| Feature | KPV Peptide |
|---|---|
| Type | Tripeptide (α-MSH derivative) |
| Mechanism | Anti-inflammatory via NF-κB suppression |
| Key Use | Barrier protection, epithelial inflammation |
| Research Status | RUO (Research Use Only) |
| Routes Studied | Topical, intraperitoneal, enema, oral in protected form |
| Non-pigmenting? | Yes |
